Neurontin Dosage and Administration Guidelines

Dosage Adjustments for Renal Impairment

For adults with renal impairment receiving Gabapentin Gastroretentive Tablets, dosage adjustments are necessary based on creatinine clearance levels.​ The adjusted dosage regimen ranges from 600 mg to 1.​8 g once daily, with specific initiation guidelines and titration schedules for optimal patient response and tolerability.

Dosage for Epilepsy with Partial Onset Seizures

The starting dose for patients 12 years of age and above with epilepsy and partial onset seizures is typically 300 mg three times a day.​ The maintenance dosage recommended for Neurontin is between 300 mg to 600 mg three times a day.​ Clinical studies have shown that doses up to 2400 mg per day are generally well-tolerated, with some patients receiving up to 3600 mg per day in certain cases.

Dosage for Postherpetic Neuralgia

In adults with postherpetic neuralgia, Neurontin may be initiated on Day 1 with a single 300 mg dose, increased to 600 mg/day on Day 2 (300 mg twice a day), then further increased to 900 mg/day on Day 3 (300 mg three times a day). The dose can be titrated up to 1800 mg/day as needed for pain relief.

Dosage for Children (5 to 11 years of age)

For children aged 5 to 11 years, the recommended maintenance dose of Neurontin ranges from 25 mg/kg/day to 35 mg/kg/day, administered in three divided doses. Neurontin can be given as an oral solution, capsule, or tablet, with doses up to 50 mg/kg/day being well-tolerated in clinical studies.​

Special Considerations for Gabapentin Extended-Release Tablets

Gabapentin extended-release tablets, like Horizant, are specifically used to treat conditions such as restless legs syndrome. They are part of the anticonvulsant class of medications and work by decreasing abnormal neuronal activity.​ The typical maximum daily dosage for Gabapentin extended-release tablets should not exceed 1800 mg per day, with specific titration schedules given for optimal symptom relief.​

Pharmacokinetics and Drug Metabolism

Gabapentin is primarily excreted unchanged in the urine and not appreciably metabolized in humans.​ The elimination half-life of gabapentin is approximately 5 to 7 hours and is unaffected by dose or repeated dosing.​ The bioavailability of gabapentin is not dose-proportional, with higher doses resulting in decreased bioavailability.​ Factors like creatinine clearance influence plasma clearance and renal clearance of gabapentin, making dose adjustments necessary based on renal function.​

Adverse Events and Warnings

Upon abrupt discontinuation of Neurontin, adverse events such as anxiety, insomnia, nausea, pain, and sweating may occur.​ Additionally, changes in libido, ejaculation disorders, and anorgasmia have been reported.​ It is crucial to monitor for potential increases in suicidal thoughts, behavior, or mood changes when using antiepileptic drugs like Neurontin.​ Patients are advised to discontinue therapy and seek medical attention immediately in cases of anaphylaxis, angioedema, or signs of CNS depression.​ Furthermore, caution is advised regarding concomitant use with other sedatives or ethanol, as well as gradual tapering when discontinuing the medication to prevent seizure frequency escalation.​

Pregnancy and Breastfeeding Considerations

During pregnancy, there is limited data on the developmental risks associated with the use of Neurontin in pregnant women.​ Animal studies have shown developmental toxicity at doses similar to or lower than those used clinically.​ It is important to weigh the potential benefits against the risks for both the mother and the fetus.​ Neurontin is excreted in human milk, but the effects on the breastfed infant and milk production are unknown.​ When considering the use of Neurontin during breastfeeding, the clinical need for the medication should be evaluated alongside any potential adverse effects on the infant.​